1,914 results match your criteria coinfection hbv

Acute Kidney Injury and Jaundice in a Patient With Concurrent Severe Malaria and Acute Exacerbation of Hepatitis B.

J Investig Med High Impact Case Rep 2021 Jan-Dec;9:23247096211043712

Gatot Soebroto Army Central Hospital, Jakarta, Indonesia.

Patients chronically infected with hepatitis B virus (HBV) may travel to areas with high endemicity of malaria. The overlap between malaria and HBV infection can be clinically severe and present a diagnostic challenge as both diseases manifest similar symptoms. This case describes a fatal case of a 43-year-old man with chronic HBV infected with malaria that presents as acute kidney injury (AKI) and jaundice following a trip to malaria-endemic region. Read More

View Article and Full-Text PDF
September 2021

Coinfection of Hepatitis B and Hepatitis C Virus in Patients With Human Immunodeficiency Virus.

Cureus 2021 Jul 19;13(7):e16474. Epub 2021 Jul 19.

Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.

Background Coinfection of viral hepatitis and human immunodeficiency virus (HIV) is not uncommon in Pakistan. Coinfection of hepatitis B virus (HBV) and hepatitis C virus (HCV) with HIV is associated with a poor prognosis. The current study evaluated the occurrence of coinfection of HBV/HIV and HCV/HIV in Peshawar, Khyber Pakhtunkhwa, Pakistan. Read More

View Article and Full-Text PDF

Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study.

J Antimicrob Chemother 2021 Aug 30. Epub 2021 Aug 30.

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Paris F75012, France.

Objectives: To determine the extent of hepatitis B virus (HBV) suppression and its association with seroclearance of hepatitis 'e' antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HIV/HBV-coinfected patients undergoing long-term tenofovir-based antiretroviral therapy (ART).

Methods: We prospectively followed 165 HIV/HBV-coinfected patients undergoing tenofovir-based ART. Serum HBV-DNA viral loads and HBeAg and HBsAg status were obtained at tenofovir initiation and every 6-12 months. Read More

View Article and Full-Text PDF

Hemophagocytic lymphohistiocytosis associated with HBV-HCV coinfection in adult: Case report.

Clin Case Rep 2021 Aug 6;9(8):e04328. Epub 2021 Aug 6.

Hematology Department Cheikh Khalifa International University Hospital Casablanca Morocco.

The case reported is the first case in Morocco to our knowledge. The reason for sharing this case is to facilitate knowledge transfer between physicians, caring for adult patients with HLH, with the aim to improve the outcome of these patients. Read More

View Article and Full-Text PDF

Changing Epidemiology of Hepatitis B Virus and Hepatitis C Virus Coinfection in a Human Immunodeficiency Virus-Positive Population in China: Results From the Third and Fourth Nationwide Molecular Epidemiologic Surveys.

Clin Infect Dis 2021 08;73(4):642-649

State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Changping District, Beijing, China.

Background: The transmission of human immunodeficiency virus (HIV) and hepatitis B virus (HBV)/hepatitis C virus (HCV) is similar in modes/routes and related risk factors. Understanding the long-term changing epidemiology of HIV, HBV, and HCV coinfection is important for evaluation of existing disease control policy and healthcare planning. We describe HBV and HCV coinfection based on the latest 2 nationwide molecular epidemiologic surveys of HIV infection in mainland China in 2007 and 2015. Read More

View Article and Full-Text PDF

Detection and Genetic Characterization of Hepatitis B and D Viruses: A Multi-Site Cross-Sectional Study of People Who Use Illicit Drugs in the Amazon Region.

Viruses 2021 07 15;13(7). Epub 2021 Jul 15.

Programa de Pós-Graduação em Biologia Ambiental, Universidade Federal do Pará, Bragança 68600-000, PA, Brazil.

Hepatitis B (HBV) and delta (HDV) viruses are endemic in the Amazon region, but vaccine coverage against HBV is still limited. People who use illicit drugs (PWUDs) represent a high-risk group due to common risk behavior and socioeconomic factors that facilitate the acquisition and transmission of pathogens. The present study assessed the presence of HBV and HBV-HDV co-infection, identified viral sub-genotypes, and verified the occurrence of mutations in coding regions for HBsAg and part of the polymerase in HBV-infected PWUDs in municipalities of the Brazilian states of Amapá and Pará, in the Amazon region. Read More

View Article and Full-Text PDF

Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review.

Viruses 2021 07 11;13(7). Epub 2021 Jul 11.

Institut Pierre Louis d'Épidémiologie et de Santé Publique, INSERM, IPLESP, Sorbonne Université, 75012 Paris, France.

In individuals infected with hepatitis B virus (HBV), the loss of hepatitis B surface antigen (HBsAg) is the ultimate therapeutic goal, which defines "functional cure." For individuals living with human immunodeficiency virus (HIV), functional cure occurs roughly 2 per 100 person-years during potent anti-HBV containing antiretroviral therapy. Although this rate may be higher than expected in treated HBV mono-infected individuals, rates of functional cure widely vary between studies (0. Read More

View Article and Full-Text PDF

Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients.

Liver Int 2021 Jul 16. Epub 2021 Jul 16.

Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Background And Aims: Despite vaccination recommendations, hepatitis B (HBV) and D (HDV) coinfections are common in HIV+individuals.

Methods: HBV immunization status (anti-HBs) as well as HBV (HBsAg/HBV-DNA) and HDV (anti-HDV) coinfection rates were assessed in 1870 HIV+individuals at HIV diagnosis (baseline, BL) and last follow-up (FU).

Results: Sixty-eight (3. Read More

View Article and Full-Text PDF

Increased Inflammation and Liver Disease in HIV/HBV-coinfected Individuals.

J Acquir Immune Defic Syndr 2021 Jul 14. Epub 2021 Jul 14.

Kombewa Clinical Research Center, U.S. Army Medical Research Directorate-Africa, Kombewa, Kenya U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA Makerere University Walter Reed Project, Kampala, Uganda.

Objective: HIV and HBV co-infection can accelerate morbidity and mortality, especially in sub-Saharan Africa where both infections are common. While inflammation contributes to disease progression, more information is needed to better understand the pathology. This study compared markers of cirrhosis and inflammation in HIV/HBV coinfected individuals compared to monoinfected and uninfected patients. Read More

View Article and Full-Text PDF

The global and regional prevalence of hepatitis C and B co-infections among prisoners living with HIV: a systematic review and meta-analysis.

Infect Dis Poverty 2021 Jul 1;10(1):93. Epub 2021 Jul 1.

Department of Epidemiology, School of Public Health, Shahroud University of Medical Sciences, Shahroud, Iran.

Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are common among individuals with human immune deficiency virus (HIV) infection worldwide. In this study, we did a systematic review and meta-analysis of the published literature to estimate the global and regional prevalence of HCV, HBV and HIV coinfections among HIV-positive prisoners.

Methods: We searched PubMed via MEDLINE, Embase, the Cochrane Library, SCOPUS, and Web of science (ISI) to identify studies that reported the prevalence of HBV and HCV among prisoners living with HIV. Read More

View Article and Full-Text PDF

Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?

Viruses 2021 Jun 1;13(6). Epub 2021 Jun 1.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20082 Milan, Italy.

Direct-acting antivirals (DAA) have revolutionized the treatment of patients with chronic hepatitis C virus (HCV) infection, possibly leading to HCV elimination by 2030 as endorsed by the World Health Organization (WHO). However, some patients belonging to the so-called unique or special populations are referred to as difficult-to-treat due to unreached sustained virological response, potential drug side effects or interactions or co-morbidities. Several years after the DAA introduction and on the basis of excellent findings in terms of efficacy and safety, some doubts arise around the exact meaning of the special population designation and whether this group of patients actually exists. Read More

View Article and Full-Text PDF

Persistent chronic immune activation in HIV/HBV-coinfected patients after antiretroviral therapy.

J Viral Hepat 2021 Jun 29. Epub 2021 Jun 29.

Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.

We studied the characteristics of immune activation and investigated the underlying mechanisms in patients with human immunodeficiency virus-1/hepatitis B virus (HIV/HBV) coinfection after receiving HBV-active antiretroviral therapy. Forty patients with HIV/HBV coinfection, 38 patients with HIV monoinfection and 20 healthy controls were enrolled. CD4 count, HIV load, HBV load, markers of immune activation and regulatory T-cell (Treg cell) frequency were assessed and compared between HIV-monoinfected and HIV/HBV-coinfected patients at week 0 (baseline), 12, 24, 36 and 48 after the onset of HBV-active antiretroviral therapy. Read More

View Article and Full-Text PDF

HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018.

Euro Surveill 2021 06;26(25)

The members of the GeSIDA 8514 Study Group have been listed under Investigators.

BackgroundRecent and reliable estimates on the prevalence of coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in Europe are lacking.AimLeveraged on a study designed to assess HIV/HCV coinfection prevalence, we assessed the prevalence of HIV/HBV coinfection in Spain in 2018 and compared the results with five similar studies performed since 2002.MethodsThis cross-sectional prevalence study was carried out in 43 centres, and patients were selected using simple random sampling. Read More

View Article and Full-Text PDF

The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report.

Acta Dermatovenerol Alp Pannonica Adriat 2021 Jun;30(2):71-73

Dermatology Unit, Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy.

Atopic dermatitis (AD) is a chronic immune-mediated inflammatory disease typical of childhood that can also affect adults. AD is clinically characterized by intensely pruritic eczematous lesions. The burden of this disease and its impact on quality of life are often substantial. Read More

View Article and Full-Text PDF

Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan.

J Microbiol Immunol Infect 2021 Jun 4. Epub 2021 Jun 4.

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine and Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:

Purpose: To clarify and investigate the prevalence and clinical impact of hepatitis D virus (HDV) infection in Taiwan's communities.

Methods: HDV infection in patients with chronic hepatitis B viral (HBV) infection was examined using an anti-HDV antibody in Yonghe Cardinal Tien Hospital (YCTH), a district hospital in Taiwan. Clinical characteristics of anti-HDV-positive and anti-HDV-negative patients were collected and compared. Read More

View Article and Full-Text PDF

Is hepatitis delta underestimated?

Liver Int 2021 06;41 Suppl 1:38-44

Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.

Hepatitis D virus may be underestimated because it is a significant problem in HBsAg-positive patients, especially those who inject drugs, have HIV or HCV co-infections and/or live in certain endemic regions. In the past few decades, the prevalence of HDV was expected to have decreased as a result of improvements in public healthcare policies and universal HBV vaccination programs. However, HDV has continued to spread in low-income countries, with local outbreaks and migration to less endemic areas, so that its prevalence has remained stable or even increased in certain regions. Read More

View Article and Full-Text PDF

Direct antiviral agents in hepatitis C virus related liver disease: Don't count the chickens before they're hatched.

World J Gastroenterol 2021 Jun;27(21):2771-2783

Department of Internal Medicine, V. Cervello Hospital, Palermo 90146, Italy.

Since molecules with direct-acting antiviral (DAA) became available, the landscape of the treatment of hepatitis C virus (HCV) infection has completely changed. The new drugs are extremely effective in eradicating infection, and treatment is very well tolerated with a duration of 8-12 wk. This review aims to report the outstanding clinical benefits of DAA and to highlight their critical disadvantages, identifying some clinically relevant hot topics. Read More

View Article and Full-Text PDF

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.

Gut 2021 Sep 8;70(9):1782-1794. Epub 2021 Jun 8.

Division of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable outcome, with many patients developing liver cirrhosis, liver failure and eventually hepatocellular carcinoma within 5-10 years. The identification of the HBV/HDV receptor and the development of novel in vitro and animal infection models allowed a more detailed study of the HDV life cycle in recent years, facilitating the development of specific antiviral drugs. Read More

View Article and Full-Text PDF
September 2021

Drug-resistant and immune-escape hepatitis B virus mutants, occult hepatitis B infection and coinfections in public hospital patients from Argentina.

Virus Genes 2021 Aug 6;57(4):327-337. Epub 2021 Jun 6.

Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET) - Universidad de Buenos Aires (UBA), Instituto de Investigaciones en Microbiología y Parasitología Médica (IMPAM), Paraguay 2155 P11 (C1121ABG), Ciudad Autónoma de Buenos Aires, Argentina.

Argentina exhibits low serological prevalence for Hepatitis B virus (HBV); however, occult hepatitis B infection (OBI) has been reported in blood donors, Amerindians and individuals coinfected with hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV). The aim of this study was to analyze the genetic diversity of HBV and to evaluate serological marker associations and coinfections with HCV and HIV in patients attending and treated in a public hospital in the province of Buenos Aires, Argentina. A total of 189 HBV reactive samples (HBsAg and/or anti-HBc) were analyzed for HBV DNA characterization. Read More

View Article and Full-Text PDF

Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection.

Viruses 2021 05 13;13(5). Epub 2021 May 13.

Department of Surgery, Campus Virchow-Klinikum and Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.

Patients after LT due to combined HBV/HDV infection are considered to be high-risk patients for recurrence of hepatitis B and D. To date, life-long prophylaxis with hepatitis B immunoglobulin (HBIG) and replication control with nucleos(t)ide analogs (NA) remains standard. We examined the course of 36 patients that underwent liver transplantation from 1989 to 2020 for combined HBV/HDV-associated end-stage liver disease in this retrospective study. Read More

View Article and Full-Text PDF

Seroepidemiology of Hepatitis B and C Virus Infections: A Five-Year Retrospective Study among Blood Donors in Saboba District in the Northern Region of Ghana.

Biomed Res Int 2021 11;2021:5599705. Epub 2021 May 11.

Department of Medical Laboratory Sciences, School of Allied Health Sciences, University of Health and Allied Sciences, Ho, Ghana.

Methods: A five-year hospital-based retrospective study was carried out among 8605 blood donors comprising 8517 males and 88 females using data on blood donors from Saboba Assemblies of God Hospital located in the Saboba District in the Northern Region of Ghana from 2013 to 2017. Blood bank records on HBV and HCV potential blood donors who visited the hospital to donate blood were retrieved. Donor demographic details, i. Read More

View Article and Full-Text PDF
September 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) /Hepatitis B virus (HBV) Co-infected Patients: A case series and review of the literature.

Int J Clin Pract 2021 Sep 6;75(9):e14412. Epub 2021 Jun 6.

Department of Infectious Diseases and Clinical Microbiology, Bismil State Hospital, Diyarbakır, Turkey.

Objective: We aimed to determine whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/hepatitis B virus (HBV) coinfection affects liver function and the outcome of the disease.

Methods: One hundred fifty-six laboratories confirmed SARS-CoV-2 positive patients were followed up between 1 July and 31 December 2020 and analysed retrospectively. Continuous variables were compared with the independent samples t-test. Read More

View Article and Full-Text PDF
September 2021

Diagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi.

BMC Infect Dis 2021 May 27;21(1):487. Epub 2021 May 27.

Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Ronald Ross Building, 8 West Derby Street, Liverpool, L69 7BE, UK.

Background: The World Health Organization (WHO) has targeted a reduction in viral hepatitis-related mortality by 65% and incidence by 90% by 2030, necessitating enhanced hepatitis B treatment and prevention programmes in low- and middle-income countries. Hepatitis B e antigen (HBeAg) status is used in the assessment of eligibility for antiviral treatment and for prevention of mother-to-child transmission (PMTCT). Accordingly, the WHO has classified HBeAg rapid diagnostic tests (RDTs) as essential medical devices. Read More

View Article and Full-Text PDF

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.

World J Gastroenterol 2021 May;27(18):2177-2192

Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok 15-540, Poland.

Background: The introduction of direct-acting antiviral drugs into clinical practice has revolutionized the treatment of chronic hepatitis C, making it highly effective and safe for patients. However, few researchers have analyzed the factors causing therapy failure in some patients.

Aim: To analyze factors influencing the failure of direct antiviral drugs in the large, multicenter EpiTer-2 cohort in a real-world setting. Read More

View Article and Full-Text PDF

Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis.

Lancet Infect Dis 2021 May 20. Epub 2021 May 20.

Department of Medicine, All India Institute of Medical Sciences, Delhi, India.

HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) are commonly encountered blood-borne infectious microorganisms. Infection with these viruses typically requires long-lasting drug therapy. Coinfections, especially with tuberculosis, pose a challenge to the creation of a regimen with adequate efficacy and minimal drug-drug interactions and adverse effects. Read More

View Article and Full-Text PDF

Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition.

Semin Immunopathol 2021 Aug 21;43(4):535-548. Epub 2021 May 21.

Hamburg-Lübeck-Borstel-Riems partner site, German Center for Infection Research (DZIF), Hamburg, Germany.

Chronic infections with human hepatitis viruses continue to be a major health burden worldwide. Despite the availability of an effective prophylactic vaccine against the hepatitis B virus (HBV) and of antiviral agents efficiently suppressing HBV replication, more than 250 million people are currently chronically infected with this hepatotropic DNA virus, and resolution of chronic hepatitis B (CHB) is rarely achieved. Moreover, coinfection with the hepatitis D virus (HDV), a human RNA satellite virus requiring the envelope proteins of HBV for productive viral spreading, substantially aggravates the disease course of CHB. Read More

View Article and Full-Text PDF

Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV.

Expert Opin Drug Saf 2021 May 27:1-16. Epub 2021 May 27.

UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italia.

Different single-tablet regimens (STRs), containing one or two nucleoside reverse transcriptase inhibitors (NRTIs) plus an anchor drug, are available for the use in naïve, HIV-infected patients. Despite some restrictions in the use of particular regimens in certain situations (e.g. Read More

View Article and Full-Text PDF

Estimating Prevalence of Hepatitis B Virus Coinfection Among Adults With Tuberculosis: A Systematic Review With Meta-analysis.

J Clin Gastroenterol 2021 Apr 9. Epub 2021 Apr 9.

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto Department of Medicine, Alameda Health System-Highland Hospital Medical Library Services, Alameda Health System, Oakland Department of Family and Community Medicine, University of California, San Francisco, CA Tuberculosis Section, Division of Communicable Disease Control and Prevention, Alameda County Public Health Department, San Leandro, CA.

Background: While patients with hepatitis B virus (HBV) infection and tuberculosis (TB) have similar risk factors, little is known regarding the prevalence of HBV and TB coinfection. We aim to evaluate the prevalence of HBV among patients with TB across world regions.

Methods: We systematically reviewed the literature using PubMed from inception through September 1, 2019, to identify studies that provided data to calculate HBV coinfection prevalence among adults with TB infection. Read More

View Article and Full-Text PDF

Co-infection With Hepatitis B in Tuberculosis Patients on Anti-tuberculosis Treatment and the Final Outcome.

Cureus 2021 Apr 12;13(4):e14433. Epub 2021 Apr 12.

Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.

Background The occurrence of both tuberculosis (TB) and concomitant hepatitis B virus (HBV) is likely to be associated with poor patient outcomes and poor treatment response. Objective To assess whether tuberculosis patients with concomitant hepatitis B virus infection were prone to poorer outcomes and treatment response. Methodology A case-control study was undertaken at the Tuberculosis Centre, DHQ Bagh Azad Kashmir and Pulmonology Department, Lady Reading Hospital, Peshawar, between March 2020 and August 2020. Read More

View Article and Full-Text PDF

Current situation of viral hepatitis in Egypt.

Microbiol Immunol 2021 Sep 21;65(9):352-372. Epub 2021 Aug 21.

Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.

An estimated 8-10 million people suffer from viral hepatitis in Egypt. Hepatitis A virus (HAV) and hepatitis E virus (HEV) are the major causes of viral hepatitis in Egypt as 50% or more of the Egyptian population are already exposed to HAV infection by the age of 15. In addition, over 60% of the Egyptian population test seropositive for anti-HEV in the first decade of life. Read More

View Article and Full-Text PDF
September 2021